Evidence map›Paper›PMID 36644285›Full record

ArticleJACC. Basic to translational science2022

Safety and Tolerability of Nicotinamide Riboside in Heart Failure With Reduced Ejection Fraction.

Dennis D Wang, Sophia E Airhart, Bo Zhou, Laura M Shireman, Siyi Jiang, Carolina Melendez Rodriguez, James N Kirkpatrick, Danny D Shen, Rong Tian, Kevin D O'Brien

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JACC. Basic to translational science, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 63 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
63citing papers in PubMed, 1 pooled it
10.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

63 citing papers in PubMed, 1 synthesis or guideline pooled it, 74 citations in OpenAlex.

  1. Pooled it
  2. Effect of Nicotinamide Adenine Dinucleotide on Heart Failure Caused by Ischemic Cardiomyopathy: A Randomized, Placebo-Controlled Trial.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2026
    Trial
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. Review
  19. NADInternational journal of molecular sciences · 2026
    Article
  20. Article

3 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Dennis D WangDivision of Cardiology, Department of Medicine, University of Washington, Seattle, Washington, USA.
Sophia E AirhartDivision of Cardiology, Department of Medicine, University of Washington, Seattle, Washington, USA.
Bo ZhouMitochondrial and Metabolism Center, Department of Anesthesiology and Pain Medicine, University of Washington, Seattle, Washington, USA.
Laura M ShiremanSchool of Medicine and Department of Pharmaceutics, School of Pharmacy, University of Washington, Seattle, Washington, USA.
Siyi JiangMitochondrial and Metabolism Center, Department of Anesthesiology and Pain Medicine, University of Washington, Seattle, Washington, USA.
Carolina Melendez RodriguezHarborview Medical Center, University of Washington, Seattle, Washington, USA.
James N KirkpatrickDivision of Cardiology, Department of Medicine, University of Washington, Seattle, Washington, USA.
Danny D ShenSchool of Medicine and Department of Pharmaceutics, School of Pharmacy, University of Washington, Seattle, Washington, USA.
Rong TianMitochondrial and Metabolism Center, Department of Anesthesiology and Pain Medicine, University of Washington, Seattle, Washington, USA.
Kevin D O'BrienDivision of Cardiology, Department of Medicine, University of Washington, Seattle, Washington, USA.
University of Washington · USProvidence St. Vincent Medical Center · US

Funding

NAD+/NADH ratio, protein acetylation and mitochondrial functionR01HL110349 · NHLBI · UNIVERSITY OF WASHINGTON · PI TIAN, RONG · 2011 to 2020
$5.7M
Mechanistic Studies of NAD+/NADH in Human Heart FailureR01HL144937 · NHLBI · UNIVERSITY OF WASHINGTON · PI O'BRIEN, KEVIN D., TIAN, RONG · 2019 to 2023
$4.2M
NHLBI NIH HHS R01 HL110349NHLBI NIH HHS R01 HL144937
6 · The paper itself

Abstract

The mitochondrial dysfunction characteristic of heart failure (HF) is associated with changes in intracellular nicotinamide adenine dinucleotide (NAD

Indexed as

AE, adverse eventE/e′, ratio of the early transmitral flow velocity to the early diastolic tissue velocityGLS, global longitudinal strainheart failure with reduced ejection fractionHF, heart failureHFrEFHFrEF, heart failure with reduced rejection fractionIL, interleukinLV, left ventricularmitochondrial dysfunctionNAD+NAD+, nicotinamide adenine dinucleotidenicotinamide adenine dinucleotidenicotinamide ribosideNLRP3, NOD-like receptor family pyrin domain containing 3NRNR, nicotinamide ribosidePBMC, peripheral blood mononuclear cellsterile inflammationTNF, tumor necrosis factor

Identifiers

PMID36644285
PMCPMC9831861
OpenAlexW4295749542

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.